Auxier Asset Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.73M Sell
60,579
-395
-0.6% -$10.5K 0.23% 86
2026
Q2
$1.47M Sell
60,974
-785
-1% -$20.5K 0.2% 97
2026
Q1
$1.73M Buy
61,759
+850
+1% +$22.6K 0.25% 87
2025
Q4
$1.52M Sell
60,909
-3,830
-6% -$96.6K 0.21% 93
2025
Q3
$1.65M Sell
64,739
-600
-0.9% -$14.8K 0.23% 87
2025
Q2
$1.58M Buy
65,339
+281
+0.4% +$6.55K 0.23% 84
2025
Q1
$1.65M Sell
65,058
-470
-0.7% -$12.3K 0.25% 83
2024
Q4
$1.74M Sell
65,528
-2,725
-4% -$73.9K 0.27% 83
2024
Q3
$1.98M Sell
68,253
-525
-0.8% -$15.3K 0.29% 80
2024
Q2
$1.92M Buy
68,778
+243
+0.4% +$6.69K 0.3% 77
2024
Q1
$1.9M Sell
68,535
-2,995
-4% -$83.1K 0.29% 81
2023
Q4
$2.06M Sell
71,530
-570
-0.8% -$17.2K 0.33% 75
2023
Q3
$2.39M Sell
72,100
-250
-0.3% -$8.84K 0.41% 68
2023
Q2
$2.65M Buy
72,350
+4,664
+7% +$182K 0.44% 66
2023
Q1
$2.76M Buy
67,686
+670
+1% +$28.9K 0.48% 63
2022
Q4
$3.43M Sell
67,016
-850
-1% -$40.8K 0.59% 47
2022
Q3
$2.97M Sell
67,866
-1,562
-2% -$75.9K 0.57% 50
2022
Q2
$3.64M Sell
69,428
-790
-1% -$40.3K 0.65% 45
2022
Q1
$3.64M Sell
70,218
-4,955
-7% -$257K 0.58% 52
2021
Q4
$4.44M Sell
75,173
-598
-0.8% -$29.6K 0.69% 47
2021
Q3
$3.26M Sell
75,771
-650
-0.9% -$28.8K 0.55% 54
2021
Q2
$2.99M Sell
76,421
-2,930
-4% -$114K 0.5% 60
2021
Q1
$2.88M Sell
79,351
-5,675
-7% -$201K 0.49% 60
2020
Q4
$3.13M Sell
85,026
-100
-0.1% -$3.67K 0.58% 58
2020
Q3
$3.12M Buy
85,126
+453
+0.5% +$16.7K 0.65% 50
2020
Q2
$2.77M Buy
84,673
+11,405
+16% +$408K 0.61% 52
2020
Q1
$2.39M Sell
73,268
-897
-1% -$32.2K 0.6% 47
2019
Q4
$2.91M Sell
74,165
-836
-1% -$31.4K 0.54% 54
2019
Q3
$2.7M Buy
75,001
+21
+0% +$805 0.54% 57
2019
Q2
$3.25M Buy
74,980
+1,775
+2% +$74.3K 0.65% 50
2019
Q1
$3.11M Buy
73,205
+1,125
+2% +$47.5K 0.64% 49
2018
Q4
$3.15M Sell
72,080
-3,800
-5% -$166K 0.7% 46
2018
Q3
$3.34M Sell
75,880
-300
-0.4% -$12.2K 0.63% 48
2018
Q2
$2.76M Sell
76,180
-2,100
-3% -$75.6K 0.55% 59
2018
Q1
$2.78M Sell
78,280
-338
-0.4% -$12.2K 0.56% 59
2017
Q4
$2.85M Sell
78,618
-2,450
-3% -$88.1K 0.55% 57
2017
Q3
$2.89M Sell
81,068
-4,600
-5% -$156K 0.59% 56
2017
Q2
$2.88M Buy
85,668
+800
+0.9% +$26.6K 0.59% 54
2017
Q1
$2.9M Sell
84,868
-625
-0.7% -$20.8K 0.61% 56
2016
Q4
$2.78M Buy
85,493
+478
+0.6% +$15.4K 0.6% 56
2016
Q3
$2.88M Sell
85,015
-884
-1% -$31.2K 0.64% 52
2016
Q2
$3.02M Hold
85,899
– – 0.69% 51
2016
Q1
$2.55M Sell
85,899
-325
-0.4% -$9.8K 0.6% 53
2015
Q4
$2.78M Sell
86,224
-98
-0.1% -$3.25K 0.63% 53
2015
Q3
$2.71M Hold
86,322
– – 0.63% 53
2015
Q2
$2.89M Sell
86,322
-12,607
-13% -$433K 0.6% 54
2015
Q1
$3.44M Sell
98,929
-45,749
-32% -$1.53M 0.7% 50
2014
Q4
$4.51M Sell
144,678
-950
-0.7% -$28.7K 0.9% 43
2014
Q3
$4.31M Sell
145,628
-28
-0% -$828 0.9% 45
2014
Q2
$4.32M Sell
145,656
-225
-0.2% -$6.76K 0.88% 42
2014
Q1
$4.69M Sell
145,881
-13,443
-8% -$422K 1% 38
2013
Q4
$4.88M Sell
159,324
-7,550
-5% -$232K 1.03% 36
2013
Q3
$4.79M Hold
166,874
– – 1.11% 34
2013
Q2
$4.67M Hold
166,874
– – 1.13% 34

Other funds holding PFE

Auxier Asset Management's PFE Position: Q3 2026 in Review

Auxier Asset Management reduced its Pfizer (PFE) stake by 0.65% in Q3 2026, selling an estimated $10.5K and leaving 60,579 shares worth $1.73M. The position accounts for 0.23% of the portfolio, ranked #86.

Auxier Asset Management first reported a position in PFE in Q2 2013 and has held it in 54 quarters since. The position peaked at $4.88M in Q4 2013. 2,918 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Auxier Asset Management held 60,579 shares of Pfizer worth $1.73M as of Q3 2026.
  • Auxier Asset Management sold 395 Pfizer shares in Q3 2026, an estimated $10.5K.
  • Pfizer made up 0.23% of Auxier Asset Management's portfolio in Q3 2026, its #86 holding.
  • Auxier Asset Management first reported a position in Pfizer in Q2 2013 and has held it in 54 quarters since.
  • Auxier Asset Management's Pfizer position peaked at $4.88M in Q4 2013.
  • 2,918 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Auxier Asset Management's 13F filing for Q3 2026, filed 18 Nov 2026.